Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Department of Microbiology and, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Indian J Pharmacol. 2022 May-Jun;54(3):216-220. doi: 10.4103/ijp.ijp_783_20.
Drug information can be obtained from various drug information sources that were available as government (National Formulary of India [NFI]; Central Drugs Standard Control Organization [CDSCO]), as well as commercial documents (Current Index of Medical Specialties [CIMS] and Monthly Index of Medical Specialties [MIMS]). Irrational drug usage may happen due to wide variation in the information available in these sources. In this study, we tried to assess these variations in a sample of drugs for the acute-specific management of migraine with ergot and Triptans antimigraine drugs in drug information sources such as NFI, CIMS, MIMS, and CDSCO. Scoring was done for various drug information based on the completeness of information about drugs used in acute-specific management of migraine. The scores for the completeness of drug information about the selected antimigraine drugs are 18.37% for CIMS (Ergotamine, Sumatriptan, Rizatriptan, and Zolmitriptan), 21.1% for NFI (Dihydroergotamine, Sumatriptan), 72.79% for MIMS (Ergotamine tartrate, Sumatriptan, Rizatriptan, Naratriptan, zolmitriptan, Almotriptan) and 21.77% for CDSCO (Ergotamine tartrate, Sumatriptan, Rizatriptan, Naratriptan, Zolmitriptan, eletriptan and almotriptan). The information for the antimigraine drugs available from various sources found to so much deficient. Necessary steps need to be taken in case of government public or hard documents to streamline drug information available with them as well the commercial documents as to provide reliable drug information uniformly for promoting rational use of the drug.
药物信息可以从各种药物信息来源获取，这些来源包括政府（印度国家处方集[NFI]；中央药物标准控制组织[CDSCO]）以及商业文件（当前医学专业索引[CIMS]和医学专业月刊索引[MIMS]）。由于这些来源中提供的信息差异很大，可能会出现不合理的用药情况。在这项研究中，我们试图在 NFI、CIMS、MIMS 和 CDSCO 等药物信息来源中评估用于偏头痛急性特异性管理的麦角和曲坦类抗偏头痛药物样本中这些差异。根据用于急性特异性偏头痛管理的药物信息的完整性对各种药物信息进行评分。所选抗偏头痛药物的药物信息完整性评分分别为：CIMS（麦角胺、舒马曲坦、利扎曲坦和佐米曲坦）为 18.37%、NFI（二氢麦角胺、舒马曲坦）为 21.1%、MIMS（酒石酸麦角胺、舒马曲坦、利扎曲坦、那拉曲坦、佐米曲坦、阿莫曲坦）为 72.79%、CDSCO（酒石酸麦角胺、舒马曲坦、利扎曲坦、那拉曲坦、佐米曲坦、依来曲坦和阿莫曲坦）为 21.77%。从各种来源获得的抗偏头痛药物信息发现非常缺乏。在政府公开或硬拷贝文件的情况下，需要采取必要的措施，以简化他们提供的药物信息，以及商业文件，以提供统一的可靠药物信息，促进药物的合理使用。
